Empagliflozin (BI 10773) , ≥99% , 864070-44-0

CAS NO.：864070-44-0

Empirical Formula: C23H27ClO7

Molecular Weight: 450.91

MDL number: MFCD22566222

EINECS: 620-176-8

PRODUCT Properties

• Boiling point: 665℃
• Density: 1.398
• Flash point: 356℃
• storage temp.: 2-8°C
• solubility: insoluble in H2O; ≥20.75 mg/mL in DMSO; ≥7.06 mg/mL in EtOH with ultrasonic
• form: solid
• pka: 13.23±0.70(Predicted)
• color: White
• Stability: Hygroscopic
• InChIKey: OBWASQILIWPZMG-QZMOQZSNSA-N
• SMILES: C1=C(CC2=CC([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=CC=C2Cl)C=CC(O[C@H]2CCOC2)=C1

Description and Uses

Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was originally discovered by Boehringer Ingelheim and codeveloped and co-marketed through research collaboration with Eli Lilly and Co. It was first approved by European Medicine Agency (EMA) in May 2014, followed by the approval of the US FDA in August 2014. SGLT2 inhibitors are anewclass of glucose-lowering agents developed for the treatment of type 2 diabetes mellitus, which have a mechanism of action that is independent of pancreatic b-cell function or the degree of insulin resistance. Consequently, SGLT2 inhibitors have the potential to be of use not only as standalone therapy but also in combination with any of the existing classes of glucose-lowering agents, including insulin. Empagliflozin selectively inhibits SGLT2, which in turn prevents glucose reabsorption by excreting excess glucose in the urine.

Empagliflozin is a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.

Safety

• Symbol(GHS): GHS08
• Signal word: Warning
• Hazard statements: H361-H362
• Precautionary statements: P201-P260-P263-P264-P270-P308+P313-P201-P202-P281-P308+P313-P405-P501